PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  American Journal of Clinical Pathology

• Publication date

  2012-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1309/AJCPGA95KVSAUDMFPMID 22261449
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.

  2012cited by this paper
• SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions.

  2012cited by this paper
• The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma

  2011cited by this paper
• Retinoids regulate stem cell differentiation

  2011cited by this paper
• Pattern and clinical significance of cancer‐testis gene expression in head and neck squamous cell carcinoma

  2011cited by this paper
• PINCH‐2 expression in cancers involving serosal effusions using quantitative PCR

  2011cited by this paper
• Derivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approach

  2010cited by this paper
• Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia

  2010cited by this paper
• External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas

  2009cited by this paper
• Tenascin-X is a Novel Diagnostic Marker of Malignant Mesothelioma

  2009cited by this paper
• Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.

  2009cited by this paper
• Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.

  2009cited by this paper
• Prevalence and prognostic and predictive relevance of PRAME in breast cancer

  2008cited by this paper
• PRAME expression and clinical outcome of breast cancer

  2008cited by this paper
• Leukemia-Associated Antigens Are Critical for the Proliferation of Acute Myeloid Leukemia Cells

  2008cited by this paper
• Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas

  2008cited by this paper
• Genome-wide expression profiling reveals new insights into pathogenesis and progression of testicular germ cell tumors.

  2007cited by this paper
• Anatomic site-related expression of cancer-associated molecules in ovarian carcinoma.

  2007cited by this paper
• Cancer Genomics & Proteomics

  2007cited by this paper
• Systematic search for the best gene expression markers for melanoma micrometastasis detection

  2007cited by this paper
• Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies

  2007cited by this paper
• Biological characteristics of cancers involving the serosal cavities.

  2007cited by this paper
• Corepressors of agonist-bound nuclear receptors.

  2007cited by this paper
• Expression of cancer testis antigens in head and neck squamous cell carcinomas

  2006cited by this paper
• A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer.

  2006cited by this paper
• Gene Expression Signatures Differentiate Ovarian/Peritoneal Serous Carcinoma from Diffuse Malignant Peritoneal Mesothelioma

  2006cited by this paper
• Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications.

  2006cited by this paper
• Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors.

  2006cited by this paper
• The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling.

  2005cited by this paper
• Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo.

  2005cited by this paper
• Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability

  2005cited by this paper
• Simultaneous expression of T-cell activating antigens in renal cell carcinoma: implications for specific immunotherapy.

  2004cited by this paper
• The Tumor-Associated Antigen PRAME Is Universally Expressed in High-Stage Neuroblastoma and Associated with Poor Outcome

  2004cited by this paper
• Intratumor Heterogeneity of Cancer/Testis Antigens Expression in Human Cutaneous Melanoma Is Methylation-Regulated and Functionally Reverted by 5-Aza-2′-deoxycytidine

  2004cited by this paper
• Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes

  2003cited by this paper
• Expression of Cancer/Testis Tumor Associated Antigens in Cervical Squamous Cell Carcinoma

  2003cited by this paper
• Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program

  2003cited by this paper
• Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition.

  2002cited by this paper
• Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?

  1998cited by this paper
• Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor.

  1997cited by this paper
• Real time

  1981cited by this paper

• Anti-PD-1 Nanobody-Armored MSLN CAR-T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies.

  2025cites this paper
• Expression of PRAME in high-grade serous carcinoma is associated with higher residual disease volume and Occludin expression.

  2024cites this paper
• A comprehensive review of PRAME and BAP1 in melanoma: Genomic instability and immunotherapy targets.

  2024cites this paper
• Preferentially Expressed Antigen in Melanoma Is a Multifaceted Cancer Testis Antigen with Diverse Roles as a Biomarker and Therapeutic Target

  2023cites this paper
• PRAME Immunohistochemistry for Distinguishing Vulvar and Vaginal Melanoma From Benign Melanocytic Nevi

  2023cites this paper
• Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors

  2023cites this paper
• Immunohistochemical Detection of Cancer-Testis Antigen PRAME

  2021influential citation
• Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets

  2019cites this paper
• A five-gene reverse transcription-PCR assay for pre-operative classification of breast fibroepithelial lesions

  2016cites this paper
• Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins.

  2016cites this paper
• PRAME expression and promoter hypomethylation in epithelial ovarian cancer

  2016cites this paper
• Pre-analytical issues in effusion cytology

  2016cites this paper
• PRODUCTION OF PURIFIED HUMAN RECOMBINANT ANTIGEN PRAME AND SPECIFIC MONOCLONAL ANTIBODIES

  2015influential citation
• WT1-, PRAME- and MSLN- specific immunity in epithelial ovarian cancer

  2014cites this paper
• APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival.

  2014cites this paper
• AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma

  2013cites this paper
• The cancer testis antigen PRAME as a biomarker for solid tumor cancer management.

  2012cites this paper
• Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma

  2012cites this paper